15 March 2016 - Roche Group today announced that the U.S. FDA has accepted the company’s biologics license application and granted priority review for atezolizumab (anti-PDL1; MPDL3280A) for the treatment of people with locally advanced or metastatic urothelial carcinoma who had disease progression during or following platinum-based chemotherapy in the metastatic setting, or whose disease worsened within 12 months of receiving platinum-based chemotherapy before surgery (neoadjuvant) or after surgery (adjuvant).

For more details, go to: http://www.roche.com/media/store/releases/med-cor-2016-03-15.htm